DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.

ABSTRACT:

Importance

Preventing relapse for adults with acute myeloid leukemia (AML) in first remission is the most common indication for allogeneic hematopoietic cell transplant. The presence of AML measurable residual disease (MRD) has been associated with higher relapse rates, but testing is not standardized.

Objective

To determine whether DNA sequencing to identify residual variants in the blood of adults with AML in first remission before allogeneic hematopoietic cell transplant identifies patients at increased risk of relapse and poorer overall survival compared with those without these DNA variants.

Design, setting, and participants

In this retrospective observational study, DNA sequencing was performed on pretransplant blood from patients aged 18 years or older who had

SUBMITTER: Dillon LW 

PROVIDER: S-EPMC9993183 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature